0.28
-5.08%
Close of 9 Nov 2026, in NZD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pacific Edge
Its shares trade on NZX under the ticker PEB.NZ. It has been listed since 12 February 2003. In the fiscal year to 31 March 2025, it reported revenue of NZD 21.8m and a net loss of NZD 29.9m. At that date it held total assets of NZD 37.0m and shareholders' equity of NZD 26.1m.
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Feb 2003
- Website
- pacificedgedx.com ↗
Leadership
Pay as last reported
- Mr. Chris GallaherNon-Executive Independent Chairman of the BoardNZD 115,000
- Dr. Peter MeintjesChief Executive OfficerNZD 889,000
- Mr. Grant Edward GibsonChief Financial Officer
- Mr. Glen CostinPresident, Asia Pacific
- Mr. David LevisonPresident of Pacific Edge Diagnostics USA, since 2016NZD 53,000
- Mr. Darrell MorganChief Operating Officer
- Dr. Justin HarveyChief Technology Officer
- Prof. Parry GuilfordChief Scientific Officer
- Dr. Tamer AboushwarebChief Medical Officer
- Mr. Andrew McintoshChief Digital Officer
- Mr. Tony BarclayNon-Executive Independent DirectorNZD 60,000
- Mr. Anatole MasfenNon-Executive Independent DirectorNZD 60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 47
- Environment
- 49
- Social
- 63
- Governance
- 30
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pacific Edge Ltd has several strengths that contribute to its success in the market. The company has a strong focus on innovation and research, allowing it to develop cutting-edge diagnostic tests with high accuracy rates. Its advanced technology and expertise in molecular diagnostics give it a competitive advantage in the healthcare industry.
- Additionally, Pacific Edge Ltd has built strategic partnerships with leading healthcare providers and institutions, enabling it to expand its market reach and increase the adoption of its diagnostic tests. These partnerships also provide access to valuable data and patient samples for research and development purposes.
- Pacific Edge Ltd also faces certain weaknesses that could hinder its growth and competitiveness. One of the main weaknesses is the company's limited geographical presence. Although it has a strong presence in New Zealand, its market penetration in other regions, such as the United States, is less significant. This limits its potential customer base and revenue opportunities.
- Another weakness is the dependency on key partnerships and collaborations for data and sample acquisition. Any disruptions or termination of these partnerships could affect the company's ability to conduct research and develop new diagnostic tests.
- Pacific Edge Ltd has several opportunities for growth and expansion. The increasing demand for personalized medicine and targeted cancer treatments provides a favorable market environment for the company's molecular diagnostics tests. By leveraging its advanced technology and expertise, the company can further develop its product portfolio to cater to this growing demand.
- Furthermore, expanding its geographical presence, especially in large markets like the United States, can significantly increase Pacific Edge Ltd's customer base and revenue potential. This can be achieved through strategic partnerships, acquisitions, or establishing direct sales and distribution channels.
- Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.
- Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.
Weaknesses
- Pacific Edge Ltd also faces certain weaknesses that could hinder its growth and competitiveness. One of the main weaknesses is the company's limited geographical presence. Although it has a strong presence in New Zealand, its market penetration in other regions, such as the United States, is less significant. This limits its potential customer base and revenue opportunities.
- Another weakness is the dependency on key partnerships and collaborations for data and sample acquisition. Any disruptions or termination of these partnerships could affect the company's ability to conduct research and develop new diagnostic tests.
- Pacific Edge Ltd has several opportunities for growth and expansion. The increasing demand for personalized medicine and targeted cancer treatments provides a favorable market environment for the company's molecular diagnostics tests. By leveraging its advanced technology and expertise, the company can further develop its product portfolio to cater to this growing demand.
- Furthermore, expanding its geographical presence, especially in large markets like the United States, can significantly increase Pacific Edge Ltd's customer base and revenue potential. This can be achieved through strategic partnerships, acquisitions, or establishing direct sales and distribution channels.
- Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.
- Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.
Opportunities
- Pacific Edge Ltd has several opportunities for growth and expansion. The increasing demand for personalized medicine and targeted cancer treatments provides a favorable market environment for the company's molecular diagnostics tests. By leveraging its advanced technology and expertise, the company can further develop its product portfolio to cater to this growing demand.
- Furthermore, expanding its geographical presence, especially in large markets like the United States, can significantly increase Pacific Edge Ltd's customer base and revenue potential. This can be achieved through strategic partnerships, acquisitions, or establishing direct sales and distribution channels.
- Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.
- Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.
Threats
- Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.
- Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.